| Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants |
Amount Raised (M) | Investors; Placement Agents; Details (Date)@(M) |
| Acura Pharmaceuticals Inc. (OTC BB:ACUR) | Private placement | N/A | $14.5 | Acura raised $14.5M through an agreement with Vivo Ventures Fund VI LP, Vivo Ventures Fund VI Affiliates Fund LP, GCE Holdings LLC and certain individual investors (8/21) |
| Advanced Cell Technology Inc. (OTC BB: ACTC) | Private placement of senior secured convertible debentures and warrants | N/A | $10 | Advanced Cell is raising $10M through the private financing (8/20) |
| Alseres Pharmaceuticals Inc. (ALSE) | Private placement of a convertible promissory note | N/A | $10 | Alseres amended an agreement from May, allowing it to borrow up to $10M from Ingalls & Snyder Value Partners LP (8/14) |
| BioCryst Pharmaceuticals Inc. (BCRX) | Private placement of common stock and warrants | 8.3S and W | $65.3 | BioCryst raised $65.3M in the placement of 8.3M shares of stock and warrants, priced at $7.80 per share, to existing investors, including funds managed by Baker Brothers Investments, Kleiner Perkins Caulfield & Byers, EHS Holdings, OrbiMed Advisors, Texas Pacific Group Ventures and Stephens Investment Management (8/6) |
| Callisto Pharmaceuticals Inc. (AMEX:KAL) | Private placement of common stock and warrants | 1.12S and 22.5W | $11.2 | Callisto raised $11.2M in the placement, which was co-led by RAB Special Situations (Master) Fund Ltd. and Absolute Octane Master Fund Ltd. (8/7) |
| CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Private placement of of common stock | N/A | £6.1($12.1) | CeNeS completed a $12.1M placement (8/22)** |
| Cortex Pharmaceuticals Inc. (AMEX:COR) | Registered direct offering | 7.1S and W for 2.83S | $14.2 | Cortex raised about $14.2M; JMP Securities acted as lead placement agent, and Rodman & Renshaw LLC served as co-placement agent (8/24) |
| Curis Inc. (CRIS) | Private placement of stock and warrants | N/A | $13 | Curis raised $13M in a private placement of units each comprised of a common share and a warrant to purchase 0.35 additional common shares at $1.06375 per unit (8/6) |
| Emisphere Technologies Inc. (EMIS) | Registered direct offering | 2S and W for 0.4S | $7.57 | Emisphere raised about $7.57M, selling 2M common shares and warrants to purchase 400,000 shares, at $3.785 per unit; ThinkEquity Partners LLC is sole placement agent (8/17) |
| Encysive Pharmaceuticals Inc. (ENCY) | Registered offering | 7.7S and W for 7.7 S | $15 | Encysive raised $15M selling 7.7M shares and five-year warrants for about 7.7M shares at $1.95 each (8/21) |
| Isolagen Inc. (AMEX:ILE) | Registered direct offering | 6.76S | $13.8 | Isolagen raised $13.8M through the offering of 6.76M shares at $2.04 each (8/15) |
| Lev Pharmaceuticals Inc. (OTC BB: LEVP) | Registered direct offering | 23.3U | $35 | Lev raised $35M, selling 23.3M units priced at $1.50 each to a select group of institutional investors; each unit consists of one share of common stock and warrants to purchase an additional 0.2 shares of common stock with an exercise price of $1.86 per share (8/14) |
| Marshall Edwards Inc. (MSHL) | Private placement of common stock | 5.46S and W for 2.2S | $16.4 | Marshall Edwards raised $16.4M through the sale of about 5.46M common shares at $3 each and five-year warrants to purchase about 2.2M shares at $3.60 apiece (8/7) |
| Medicure Inc. (Canada; AMEX: MCU) | Term sheet and private placement of stock and warrants | 13.04S and W for 3.9S | $40 | Medicure received $25M in a deal with Manchester Securities Corp. to monetize a percentage of its current and potential future revenues; it also issued about 13.04M shares at $1.15 and warrants to buy about 3.9M shares; Leerink Swann, A.G. Edwards & Sons Inc., Merriman Curhan Ford & Co. and RBC Capital Markets Inc. served as financial advisors (8/21) |
| Nanogen Inc. (NGEN) | Registered offering of senior convertible notes and warrants | N/A | $20 | Nanogen raised $20M through the financing; Seven Hills Partners LLC served as the placement agent (8/27) |
| NPS Pharmaceuticals Inc. (NPSP) | Private placement of Series B stock, Sensipar royalty-backed notes and convertible notes | N/A | $150 | NPS raised $150M by issuing $50M in convertible notes to funds managed by Visium Asset Management LLC, and $100M in Series B, Sensipar royalty-backed notes (8/8) |
|
Nventa Bio- pharmaceuticals Corp. (TSX:NVN) | Private placement of units |
68.9U | C$8.6 ($8.15) |
Nventa raised $8.15M selling 68.9M units, each consisting of one common share and half a warrant (8/27) |
| Oculus Innovative Sciences Inc. (OCLS) | Private placement of common stock | 1.3S and W for 0.4S | $10.1 | Oculus raised $10.1M in a placement of 1.3M shares priced at $8 each and warrants to purchase up to 417,000 additional shares at an exercise price of $9.50 each (8/8) |
| Oragenics Inc. (AMEX:ONI) | Private placement of common stock and warrants | 4.6S and 4.6W | $1.2 | Oragenics raised $1.2M in an equity-based financing with a group of investors (8/8) |
| Oramed Pharmaceuticals Inc. (Israel;OTC BB:ORMP) | Private placement of stock and warrants | N/A | $2 | Oramed raised $2M pricing shares at 50 cents each and warrants at 75 cents each (8/6) |
| Oxis International Inc. (OTC BB:OXIS) | Investment | N/A | $0.5 | Oxis received a $500,000 investment from Synvista Therapeutics Inc. (formerly Alteon Inc.) as part of a license agreement for BXT-51072 (8/22) |
|
Peplin Ltd. (Australia; ASX:PEP) | Private placement |
N/A | A$20 ($16.9) |
Peplin raised $16.9M in a private placement (8/10) |
| Senesco Technologies Inc. (AMEX:SNT) | Private placement of convertible debentures | N/A | $5 | Senesco raised $5M in three-year, secured convertible debentures with an 8% coupon (8/8) |
| SyntheMed Inc. (OTC BB:SYMD) | Private placement of common stock | 2.8S | $2.8 | SyntheMed raised $2.8M through the sale of 2.8M shares at $1 each; it also authorized the sale of an additional 3.2M shares on the same terms (8/14) |
| Urigen Pharmaceuticals Inc. (OTC BB:URGP) | Private placement | N/A | $2.1 | Urigen raised $2.1M in a financing led by Platinum-Montaur Life Sciences LLC (8/6) |
| Vermillion Inc. (formerly Ciphergen Biosystems Inc.; VRML) | Private placement of common stock and warrants | 24.4S and W for 19.5S | $20.5 | Vermillion raised $20.5M selling 24.4M shares and warrants to purchase an additional 19.5M shares priced at 92.5 cents apiece (8/24) |
| Vyteris Inc. (OTC BB:VYHN) | Private placement of common stock | N/A | $12.7 | Vyteris raised $12.7M through the placement (8/1) |
| Notes: | ||||
| This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. # Unless otherwise indicated, shares are traded on the Nasdaq exchange @ Refers to the date of the press release.** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.N/A = Not applicable; ND = Not disclosed. AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
